Two stocks in Healthcare
AstraZeneca vs Haleon: profit, growth, debt and price compared
AstraZeneca and Haleon are each stronger on 3 of 7 figures: AstraZeneca on profit margin, sales growth and price trend; Haleon on debt, price for its expected profit and dividend.
Save both stocks to your watchlist and revisit their latest fundamentals.
| AstraZenecaAZN.L | HaleonHLN.L | |
|---|---|---|
| Net margin | Stronger: 17.7% | 14.6% |
| Revenue growth, past year | Stronger: +6.70% | +2.20% |
| Debt to equity | 66.2% | Stronger: 50.2% |
| Forward P/E | 16.1× | Stronger: 15.4× |
| Dividend yield | 1.73% | Stronger: 2.13% |
| Analysts | Buy · 22 | Buy · 18 |
| From its 200-day average | Stronger: +5.0% | −3.3% |
Share price over the past year
- AstraZeneca0.0%
- Haleon−7.1%
20 Nov 202518 Nov 2026
AstraZeneca or Haleon: which is stronger?
- AZN.L
Which is more profitable?
AstraZeneca keeps more of each sale as profit: 17.7% against 14.6%.
- AZN.L
Which is growing its sales faster?
AstraZeneca is growing its sales faster: +6.70% over the past year, against +2.20%.
- HLN.L
Which has borrowed less?
Haleon has borrowed less: its debt is 50.2% of what its shareholders own, against 66.2% for AstraZeneca.
- HLN.L
Which costs less for the profit it is expected to make?
Haleon costs less for the profit it is expected to make: 15.4× its forward earnings, against 16.1×.
- HLN.L
Which pays more in dividends?
Haleon pays more back in dividends for what a share costs: 2.13% a year, against 1.73%.
Which do analysts rate higher?
Analysts rate both the same: Buy.
- AZN.L
Which is in the stronger price trend?
AstraZeneca's price is in the stronger trend: 5.0% above its 200-day average, against 3.3% below.
What each company does
AZN.LAstraZeneca
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines.
Reports results on 9 February 2027
HLN.LHaleon
Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific.
Reports results on 25 February 2027
This comparison is just the starting point.
Discover opportunities, understand companies and compare investments in one place. See how StratDeck works
Keep researching
Where next
More comparisons
Free email
Up to speed in minutes, four times a week
Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.
Early access
Become a StratDeck founding user
Use StratDeck, tell us what's missing, and help decide what we build next.
100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.